A report by Science 37 examines key considerations for patient safety and business continuity in the clinical trial industry in light of the ongoing coronavirus pandemic.
Aiming to encourage entry of generic drugs on the market, the US FDA published a finalized guidance that regulates processes for relevant designations and expedited approvals.
The purchase is aimed at expanding the company’s specialty diagnostics offerings in sample preparation technology, assay capabilities, bioinformatics and more.
